Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1467335 MAD study in healthy volunteers
NCT02733627Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PXS-4728A in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Investigator Defined Drug-related Adverse Events up to 48 days. Started Jul 2016; status: completed.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02733627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733627.